|drug573||Buspirone + PAP therapy Wiki||1.00|
|drug3759||Zolpidem + PAP therapy Wiki||1.00|
|drug162||Acetazolamide + supplemental oxygen + PAP therapy Wiki||1.00|
|D012891||Sleep Apnea, NIH||0.50|
|D053120||Respiratory Aspiration NIH||0.29|
There is one clinical trial.
Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.
Description: CO2 reserve is the requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative.Measure: CO2 reserve Time: 120 days
Description: Central apnea indices is used to indicate the severity of central sleep apneaMeasure: Central apnea indices Time: 120 days
Description: Controller gain is a ventilatory response to changes in end-tidal PCO2Measure: Controller gain Time: 120 days
Description: Plant gain is blood gas response to a change in ventilation. This measure represents the effectiveness of the "plant" in eliminating CO2.Measure: Plant gain Time: 120 days
Description: This measure represents the activity of the carotid bodies. It is measured by the decrease in ventilation in response to a single breath of 100% oxygen.Measure: Carotid body function Time: 120 days
Description: Peripheral chemoreflex sensitivity is measured either via brief hypoxia or a single breath of CO2.Measure: Peripheral chemoreflex sensitivity Time: 120 days
Description: The nadir pressure in the upper airway (supra-glottic pressure) prior to the occurrence of an arousal.Measure: Respiratory arousal threshold Time: 120 days
Description: To assess breathing stability, the investigators will measure % stable breathing using minute ventilation (VE) and tidal volume (VT) coefficient of variation as indices of breathing instability.Measure: % stable breathing Time: 120 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports